Phase I/II Study of Venetoclax or Lenalidomide in Combination With Ublituximab and Umbralisib in Subjects With Relapsed or Refractory CLL/SLL and NHL
Phase I/II Study of Venetoclax or Lenalidomide in Combination with Ublituximab and Umbralisib in Subjects with Relapsed or Refractory CLL/SLL and NHL
Chronic Lymphocytic Leukemia|Non-Hodgkin Lymphoma
DRUG: Venetoclax|DRUG: Umbralisib|BIOLOGICAL: Ublituximab|DRUG: Lenalidomide
Determine Acceptable Adverse Events That Are Related to Treatment, 12 months
Overall Response and Complete Remission Rate, 12 months|Minimum Residual Disease (MRD), 12 months
Phase I/II Study of Venetoclax or Lenalidomide in Combination with Ublituximab and Umbralisib in Subjects with Relapsed or Refractory CLL/SLL and NHL